Melinta Therapeutics Announces Appointment of Kristen Allgor as Chief Human Resources Officer

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of Kristen Allgor as Chief Human Resources Officer, effective today.

In August of this year, Christine Ann Miller, a global pharmaceutical veteran, joined Melinta as President and Chief Executive Officer and member of the board. Under Ms. Miller’s leadership, Melinta expects to build upon its existing platform and enhance its world-class antibiotics portfolio with additional products that address therapeutic areas of critical need.

“As we reimagine Melinta’s future, developing a high-performing team culture is essential to realizing our full potential and achieving sustainable growth,” said Ms. Miller. “With Kristen’s proven track record of leading global pharmaceutical organizations through change and building high-performing teams, I’m confident she will be a strong catalyst for helping to lead Melinta through this positive transformation.”

Ms. Allgor is a seasoned human resources executive who joins Melinta from Allergan where she served as Vice President of Human Resources for the past seven years.

At Allergan, she held various roles including business partner to the commercial, finance and technology teams. In this capacity, she led teams through multiple mergers and acquisitions and implemented a global compensation platform for the company.

Prior to Allergan, Ms. Allgor held executive human resources roles at Bausch Health, Pfizer, Virgin Mobile and PepsiCo. In these roles, she focused on implementing best-in-class compensation and benefit programs.

“I am thrilled to join Melinta at this pivotal moment,” said Ms. Allgor. “It’s energizing to be a part of a team so committed to delivering life-saving therapeutics as well as cultivating and valuing the people who will drive our growth. I’m very excited to work with Christine and the rest of the Melinta team as we reimagine our future.”

About Melinta Therapeutics

Melinta Therapeutics, LLC is the largest pure-play antibiotics company, dedicated to providing innovative therapies to people impacted by acute and 
life-threatening illnesses. It currently markets four antibiotics: Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.